The Appellants in HZNP Medicines v. Actavis Laboratories saw their hopes for rehearing dashed on February 25, 2020, when the Federal Circuit issued an order denying their petitions for panel rehearing and en banc rehearing. The decision leaves intact an order finding that claims reciting “consisting essentially of” could be found indefinite based on ambiguities … Continue Reading